natgillin/translations-raw huggingface dataset:
The primary objective of the trial was progression-free survival (PFS assessed by independent radiological review); the secondary endpoints included overall survival (OS), overall response rate and duration of response.
Primarni cilj preskušanja je bila ocena in primerjava obeh terapevtskih skupin glede preživetja brez napredovanja (PFS, ki je bilo ocenjeno z neodvisnim radiološkim pregledom); med sekundarnimi opazovanimi dogodki pa so bili celokupno preživetje (OS), delež celokupnega odziva in trajanje odziva.
The primary objective of these studies was to determine if dabigatran etexilate was non-inferior to warfarin in reducing the occurrence of the primary endpoint which was the composite of recurrent symptomatic DVT and/or PE and related deaths within the 6 month treatment period.
Primarni cilj raziskav je bil ugotoviti, ali je dabigatran eteksilat enakovreden varfarinu glede na pojav primarnega opazovanega dogodka, ki je bil sestavljen iz ponovitve simptomatične GVT in/ali PE in z njima povezane umrljivosti v 6-mesečnem obdobju zdravljenja.
The primary objective of this study was to demonstrate an improvement in progression-free survival (PFS) with vandetanib compared to placebo.
Primarni cilj študije je bil ugotoviti izboljšanje preživetja brez napredovanja (PFS – progression-free survival) z vandetanibom v primerjavi s placebom.
The primary objective of this study was to rule out a greater than 10 msec effect (i.e., to demonstrate lack of effect) of a single 80 mg oral dose of vardenafil on QTc interval compared to placebo, as measured by the change in Fridericia's correction formula (QTcF=QT/RR1/3) from baseline at the 1 hour post-dose time point.
Glavni namen te študije je bil izključiti več kot 10 msec dolg učinek (to je, pokazati, da ni učinka) enkratnega 80-miligramskega peroralnega odmerka vardenafila na dobo QTc v primerjavi s placebom, ki so ga merili s spremembo Fridericiasove korekcijske formule (QTcF=QT/RR1/3) glede na osnovno vrednost 1 uro po odmerku.
The primary objective was not met.
Primarni opazovani dogodek ni bil dosežen.
The primary objective was to compare PFS in patients receiving sunitinib versus patients receiving placebo.
Primarni cilj je bil primerjati preživetje brez napredovanja bolezni (PFS) pri bolnikih, ki so prejemali sunitinib v primerjavi z bolniki, ki so prejemali placebo.
The primary objective was to demonstrate the noninferiority of T12(b.i.d.)/PR over T12(q8h)/PR.
Primarni cilj je bil dokazati primerljivost režimov T12(q8h)/PR in T12(b.i.d.)/PR.
The primary outcome measure was achievement of complete remission at 6 months defined as a Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) of 0, and off glucocorticoid therapy.
Merilo primarnega opazovanega dogodka je bila dosežena popolna remisija po 6 mesecih, opredeljena kot ocena BVAS/WG (Birmingham Vasculitis Activity Score for Wegener's Granulomatosis) 0 in brez glukokortikoidnega zdravljenja.
The primary outcome measure was the weekly mean of 24-hour average pain, which was collected in a daily diary by patients on an 11-point Likert scale.
Primarna mera izida je bilo tedensko povprečje 24-urne povprečne bolečine, kar smo zbrali iz dnevnih dnevnikov bolnikov na podlagi 11- točkovne Likertove lestvice.
The primary outcome measures were the Neuropathy Impairment Score of the Lower Limb (NIS-LL – a physician assessment of the neurologic exam of the lower limbs) and the Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN – a patient reported outcome, total quality of life score [TQOL]).
Primarni merili izida sta bili ocena okvare spodnjih okončin zaradi nevropatije [Neuropathy Impairment Score of the Lower Limb] (NIS-LL – zdravnikova ocena nevrološkega pregleda spodnjih okončin) in ocena kakovosti življenja v skladu z Norfolško študijo – diabetična nevropatija [Norfolk Quality of Life - Diabetic Neuropathy] (Norfolk QOL-DN – izid, o katerem je poročal bolnik, skupna ocena kakovosti življenja [TQOL]).
The primary outcome was the mean change in disease activity in abatacept- treated patients compared to placebo-treated patients at 6 months with a subsequent double-blind assessment of safety and efficacy of abatacept and infliximab at 12 months.
Primarni opazovani dogodek je bil srednja sprememba aktivnosti bolezni pri bolnikih, ki so prejemali abatacept v primerjavi z bolniki, ki so prejemali placebo po 6 mesecih s kasnejšim dvojno slepim vrednotenjem varnosti in učinkovitosti abatacepta in infliksimaba po 12 mesecih.
The primary pathway involves a cytosolic NADP+-linked enzyme, GHB dehydrogenase, that catalyses the conversion of sodium oxybate to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase.
Primarna pot vključuje citosolni z NADP+ povezan encim, dehidrogenazo GHB, ki katalizira pretvorbo natrijevega oksibata v sukcinat-semialdehid, ki se nato biotransformira v jantarno kislino z encimom sukcinat-semialdehid-dehidrogenaza.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66 % of the dose excreted in the urine.
Pri človeku se abakavir v glavnem presnavlja z alkoholno dehidrogenazo in glukuronidacijo, pri čemer nastane 5’-karboksilna kislina in 5’-glukuronid, ki predstavljata približno 66 % odmerka, ki se izloči z urinom.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Pri človeku se abakavir v glavnem presnavlja z alkoholno dehidrogenazo in glukuronidacijo, pri čemer nastane 5’-karboksilna kislina in 5’-glukuronid, ki predstavljata približno 66 % prejetega odmerka.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Pri človeku se abakavir v glavnem presnavlja z alkoholno dehidrogenazo in glukuronidacijo, pri čemer nastane 5’-karboksilna kislina in 5’-glukuronid, ki predstavljata približno 66% prejetega odmerka.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Pri človeku se primarno presnavlja z alkoholno dehidrogenazo in glukuroniranjem, pri čemer nastane 5’-karboksilna kislina in 5’-glukuronid, ki znašata približno 66 % prejetega odmerka.
The primary pharmacological effects of ibandronic acid on bone are not directly related to actual plasma concentrations, as demonstrated by various studies in animals and humans.
Primarni farmakološki učinki ibandronske kisline na kosti niso neposredno povezani z dejanskimi koncentracijami v plazmi, kar so pokazale številne študije pri živalih in ljudeh.
The primary pre-specified endpoint i.e. the change from baseline in FEV1 (ml) in the modified ITT (mITT) population (n=269 and 297 in studies DPM-CF-301 and DPM-CF-302, respectively) compared to control over the 26 weeks period is provided in Table 1 alongside FEV1 presented as absolute and relative change % predicted.
V preglednici 1 so prikazane primarna vnaprej določena končna točka (tj. sprememba FEV1 (ml) iz izhodiščne ravni) in absolutna ter relativna sprememba FEV1 glede na odstotkovno napovedano raven v modificirani populaciji z namenom zdravljenja (mITT) (n=269 v študiji DPM-CF-301 oz. n=297 v študiji DPM-CF-302) v primerjavi s kontrolno skupino v 26-tedenskem obdobju.
The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, (1--D- arabinofuranosyluracil or uracil arabinoside) followed by urinary excretion of ara-U.
Primarna pot izločanja citarabina je presnova v neaktivno spojino ara-U (1-β-D-arabinofuranoziluracil ali uracil arabinozid), čemur sledi izločanje le-te z urinom.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Primarni opazovani dogodek varnosti (neinferiornosti) in učinkovitosti (superiornosti) je bil sestavljen opazovani dogodek, ki je obsegal čas do prvega pojava katerega od naslednjih hudih neželenih kardiovaskularnih dogodkov: kardiovaskularne smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
The primary safety database is the Phase 3 clincal studies in which 662 subjects received 200 mg tedizolid phosphate orally and or intravenously (331/662 patients) for a maximum of 6 days.
Glavna podatkovna zbirka o varnosti vsebuje podatke iz kliničnih študij 3. faze, kjer je 662 preiskovancev prejemalo po 200 mg tedizolid fosfata peroralno in/ali intravensko (331/662 bolnikov) največ 6 dni.
The primary safety database is the Phase 3 clinical studies in which 662 subjects received 200 mg tedizolid phosphate orally and/or intravenously (331/662 patients) for a maximum of 6 days.
Glavna podatkovna zbirka o varnosti vsebuje podatke iz kliničnih študij 3. faze, kjer je 662 preiskovancev prejemalo po 200 mg tedizolid fosfata peroralno in/ali intravensko (331/662 bolnikov) največ 6 dni.
The primary safety endpoint was a composite of the following neuropsychiatric (NPS) adverse events: severe events of anxiety, depression, feeling abnormal, or hostility, and/or moderate or severe events of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behaviour or completed suicide.
Glavni opazovani dogodek varnosti je bil sestavljen iz naslednjih nevropsihiatričnih (NPS – neuropsychiatric) neželenih dogodkov: huda anksioznost, depresija, nenormalno počutje ali sovražnost in/ali zmerna do huda agitacija, agresija, blodnje, halucinacije, morilske misli, manija, panika, paranoja, psihoza, samomorilne misli, samomorilno vedenje ali samomor.
The primary substrate of the activated C1 enzyme is C4; uninhibited C1 results in diminished C4 levels.
Primarni substrat aktiviranega encima C1 je C4; nezavrt C1 povzroči zanižano raven C4.
The primary targets of toxicity included the bone marrow, lymphoreticular system, testes, the gastrointestinal tract and, at higher doses, which were lethal to 60% to 100% of rats and dogs tested, degeneration of the retina occurred.
Med glavnimi tarčnimi tkivi toksičnega delovanja so bili kostni mozeg, limforetikularni sistem, testisi in prebavila, večji odmerki, ki so bili smrtni za 60 do 100 % testiranih podgan in psov, pa so povzročili degeneracijo mrežnice.
The primary vaccination schedule consists of three doses of 0.5 ml (such as 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months) or two doses (such as 3, 5 months).
Shema osnovnega cepljenja sestoji iz treh odmerkov po 0,5 ml (v 2., 3., 4. mesecu starosti; 3., 4., mesecu starosti; 2., 4., 6. mesecu starosti) ali dveh odmerkov (v 3., 5. mesecu starosti).
The primary vaccination schedule consists of two or three doses (of 0.5 ml) which should be administered according to official recommendations (see the table below and section 5.1 for schedules evaluated in clinical trials).
Osnovno shemo cepljenja sestavljajo dva ali trije odmerki (po 0,5 ml), ki ju/jih je treba dati v skladu z uradnimi priporočili (za sheme, ki so bile ovrednotene v kliničnih preskušanjih, glejte spodnjo preglednico in poglavje 5.1).
The primary vaccination schedule consists of two or three doses of 0.5 ml administered within the first year of life according to official recommendations.
Primarno cepljenje se po uradnih priporočilih izvede z dvema ali tremi odmerki po 0,5 ml v prvem letu življenja.
The primary vaccination schedules used in clinical studies are: 2, 4 months of age without hepatitis B vaccination at birth; 2, 3, 4 months of age without hepatitis B vaccination at birth; 2, 4, 6 months of age with and without hepatitis B vaccination at birth.
Programi osnovnega cepljenja, ki so jih uporabljali v kliničnih preskušanjih, so bili naslednji: starost 2 in 4 mesece brez cepljenja proti hepatitisu B ob rojstvu; starost 2, 3 in 4 mesece brez cepljenja proti hepatitisu B ob rojstvu; starost 2, 4 in 6 mesecev z in brez cepljenja proti hepatitisu B ob rojstvu.
The primary vaccination series consists of two separate doses of 0.5 ml each, according to the following conventional schedule:
Primarno serijo za cepljenje sestavljata dva ločena odmerka po 0,5 ml, ki ju dajemo po naslednjem običajnem urniku:
The priming should be done every time you mix a new
To je treba napraviti ob vsakem mešanju novega napolnjenega injekcijskega peresnika.
The principal action of 1,25 dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption.
Glavni učinek 1,25-dihidroksivitamina D3 je povečanje absorpcije kalcija in fosfata v črevesju, uravnava pa tudi količino kalcija v serumu, izločanje kalcija in fosfata skozi ledvice ter tvorbo in resorpcijo kosti.
The principal adverse reactions associated with the administration of CellCept in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting, and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavni neželeni učinki, povezani z jemanjem zdravila CellCept v kombinaciji s ciklosporinom in kortikosteroidi, vključujejo drisko, levkopenijo, sepso in bruhanje, opisali pa so tudi višjo incidenco določenih tipov okužb (glejte poglavje 4.4).
The principal adverse reactions associated with the administration of mycophenolate mofetil in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavni neželeni učinki povezani z jemanjem mofetilmikofenolata v kombinaciji s ciklosporinom in kortikosteroidi vključujejo drisko, levkopenijo, sepso in bruhanje, opisali pa so tudi višjo incidenco določenih tipov okužb (glejte poglavje 4.4).
The principal adverse reactions associated with the administration of mycophenolate mofetil in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting, and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavni neželeni učinki, povezani z jemanjem mofetilmikofenolata v kombinaciji s ciklosporinom in kortikosteroidi, vključujejo drisko, levkopenijo, sepso in bruhanje, opisali pa so tudi višjo incidenco določenih tipov okužb (glejte poglavje 4.4).
The principal pathway involves hydrolytic oxidation of the amide moiety leading to the primary metabolite ‘safinamide acid’ (NW-1153).
Glavna pot vključuje hidrolitsko oksidacijo amidnega dela molekule, kar ustvari primarni presnovek „safinamidno kislino“ (NW-1153).
The principal route of metabolism was hydrolysis of the S- fluoromethyl carbothioate function to form the 17β-carboxylic acid metabolite.
Glavna pot presnove je hidroliza S-fluorometil karbotioata do presnovka 17- karboksilne kisline.
The principal route of metabolism was hydrolysis of the S- fluoromethyl carbothioate function to form the 17-carboxylic acid metabolite.
Glavna pot presnove je hidroliza S-fluorometil karbotioata do 17-karboksilne kisline.
The principal safety outcome (major bleeding) occurred in 6 (0.6 %) and 4 (0.8 %) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21- 2.67; safety population).
Primarni izid za oceno varnosti (velike krvavitve) se je pojavil pri 6 (0,6 %) bolnikih v skupini, ki je prejemala rivaroksaban (n = 988), in pri 4 bolnikih (0,8 %) v skupini, ki je prejemala antagoniste vitamina K (n = 499) (razmerje tveganja 0,76; 95 % interval zaupanja 0,.21 – 2,67; varnostna populacija).
The principal tests to verify the specifications are linearity, stability (reference gas precision), and precision of measurement.
Glavni testi, s katerimi preverimo specifikacije, so linearnost, stabilnost (natančnost referenčnega plina) in natančnost meritev.
The principal tests to verify the specifications are linearity, stability (reference gas precision), and precision of measurement.
Glavni testi, s katerimi preverimo specifikacije, so linearnost, stabilnost (natančnost referenčnega plina) in natančnost meritev.Vsi masni spektrometri za analizo izdihanega zraka morajo ustrezati naslednjim specifikacijam:
The principle mechanism of action of clomipramine is potentiation of the effects of 5-HT and noradrenaline in the brain by inhibiting their neuronal reuptake.
Mehanizem delovanja klomipramina je v blokiranju delovanja adrenergičnih neuronov.
The principle route of excretion in dogs is via the bile (>80%) with the remainder via the urine.
Največ se ga izloči z žolčem ( >80%), ostalo pa z urinom.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Natisnjeno Navodilo za uporabnika za zdravilo mora vsebovati ime in naslov imetnika dovoljenja za izdelavo zdravila, odgovornega za sproščanje serij tega zdravila.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Natisnjeno navodilo za uporabo mora vsebovati ime in naslov izdelovalca odgovornega za sproščanje serije.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sproščanje serij.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.‌
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.‌
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije.
The printed package leaflet of the medicinal product must state the nameand address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije.
The printing ink contains also shellac, propylene glycol and iron oxide E172, Brilliant Blue FCF E 133.
Črnilo vsebuje tudi šelak, propilenglikol, železov oksid E172 in modro FCF E133.
The printing ink contains also shellac, propylene glycol and iron oxide E172.
Črnilo vsebuje tudi šelak, propilenglikol in železov oksid E172.
The printing ink contains black iron oxide (E172) and shellac.
Tiskarsko črnilo vsebuje črni železov oksid (E172) in šelak.
The printing ink contains iron oxide black (E172), isopropyl alcohol, propylene glycol and hypromellose (E464).
Tiskarsko črnilo vsebuje črn železov oksid (E172), izopropil alkohol, propilenglikol in hipromelozo (E464).
The printing ink contains: shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527) (white ink) and shellac, iron oxide black (E172), propylene glycol (E1520) and ammonium hydroxide (E527) (black ink).
Tiskarsko črnilo vsebuje: šelak, titanov dioksid (E171), simetikon, propilenglikol (E1520) in amonijev hidroksid (E527) (belo črnilo) in šelak, črni železov oksid (E172), propilenglikol (E1520) in amonijev hidroksid (E527) (črno črnilo).
The printing ink contains: white ink - shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527).
Tiskarsko črnilo vsebuje: belo črnilo - šelak, titanov dioksid (E171), simetikon, propilenglikol (E1520) in amonijev hidroksid (E527).
The printing ink is composed of shellac, black iron oxide (E172) and propylene glycol.
Tiskarsko črnilo vsebuje šelak, črni železov oksid (E172) in propilenglikol.
The printing ink is composed of shellac, iron oxide black (E172), N-butyl alcohol, purified water, propylene glycol and ammonium hydroxide.
Tiskarska barva pa vsebuje šelak, črni železov oksid (E172), N-butil alkohol, prečiščeno vodo, propilenglikol, aluminijev hidroksid.
The printing ink used on Advagraf capsules contains soya lecithin.
Tiskarsko črnilo, ki se uporablja za označevanje kapsul Advagraf, vsebuje sojin lecitin.
The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-gp.
Predzdravilo dabigatran eteksilat je substrat efluksnega transporterja P-glikoproteina, dabigatran pa ne.
The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-gp.
Predzdravilo dabigatran eteksilat je substrat efluksnega transporterja P-gp, dabigatran pa ne.
The probability for sustained virological response varied depending upon the previous treatment regimen; see Table 19.
Verjetnost trajnega virološkega odziva je bila različna glede na prejšnjo shemo zdravljenja (glejte preglednico 19).
The probability of a poor outcome and of developing high and sustained IgG antibody titres appears higher among CRIM-negative patients (Cross Reactive Immunologic Material; patients in whom no endogenous GAA protein was detected by Western blot analysis) than among CRIM-positive patients (patients in whom endogenous GAA protein was detected by Western blot analysis).
Možnost nezadovoljivega izida in nastanka visokih in vzdrževanih titrov protiteles IgG je višja pri CRIM negativnih bolnikih (navzkrižno reaktivni imunološki material, Cross Reactive Immunologic Material; bolniki, pri katerih niso zaznali endogenega proteina GAA z Western blot analizo) kot pri CRIM pozitivnih bolnikih (bolniki, pri katerih so zaznali endogeni protein GAA z Western blot analizo).
The probability of developing MS over 24 months was 62.5% for patients given Rebif three times a week (or 75.5% for patients given Rebif once a week) compared with 85.8% for patients given placebo.
Verjetnost za razvoj multiple skleroze v 24 mesecih je bila pri bolnikih, ki so prejemali zdravilo Rebif trikrat na teden, 62,5-odstotna (75,5-odstotna pri bolnikih, ki so zdravilo Rebif prejemali enkrat tedensko), medtem ko je bila pri bolnikih, ki so prejemali placebo, 85,8-odstotna.
The probability of patients in the Ameluz group to require only 1 treatment and remain completely cleared 12 months after the photodynamic therapy was 32.3%, that of patients in the MAL group 22.4% on average with all lamps.
Verjetnost, da bodo bolniki, ki so jih zdravili z zdravilom Ameluz, potrebovali samo eno zdravljenje in bodo 12 mesecev po fotodinamičnem zdravljenju povsem očiščeni, je bila 32,3-odstotna, pri bolnikih, ki so se zdravili z MAL, pa je bila ta verjetnost v povprečju 22,4-odstotna pri uporabi vseh svetilk.
The probability of survival at 1 year was 97%, at 2 years 93% and at 3 years 91%.
Verjetnost preživetja po enem letu je bila 97 %, po dveh letih 93 %, in po treh letih 91 %.